Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
Resverlogix Corp. (”Resverlogix” or the “Company”) (TSX:RVX) announced that it has begun dosing patients in its US Phase 2 clinical trial lead by Cleveland Clinic. This trial will examine RVX-208, Resverlogix’s oral small molecule therapy for the treatment of atherosclerosis, in patients with stable coronary artery disease (CAD). This study is chaired by Dr. Steven [...]



